Graft Versus Host Diseases Market
Number of pages: 100 | Report Format: PDF | Published date: March 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.42 billion |
|
Revenue Forecast in 2031 |
US$ 12.67 billion |
|
CAGR |
14% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment Type, Disease Type and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global graft versus host diseases market was valued at US$ 3.42 billion in 2021 and is expected to register a revenue CAGR of 14% to reach US$ 12.67 billion by 2031.
Graft Versus Host Diseases Market Fundamentals
Graft versus host disease (GvHD) is a health disorder that develops following an allogeneic bone marrow or stem cell transplant. GvHD is a potentially fatal condition following a transplant with a genetically distinct individual. GvHD is segmented into two types: acute GvHD (aGvHD) and chronic GvHD (cGvHD). GVHD is a major cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation. It is the subject of ongoing research. Despite tremendous advances in understanding the pathogenesis, diagnosis, and risk factors for both acute and chronic forms of the illness, a comprehensive therapy approach remains inadequate. Corticosteroid therapy effectively treats acute and chronic forms of the condition. However, the most effective treatment for steroid-refractory illness is still debatable.
[658568]
Graft Versus Host Diseases Market Dynamics
The rising prevalence of GvHD, caused mostly by an increase in allogeneic transplants, is creating a large patient pool in need of therapy. This is one of the primary factors driving the expansion of the graft versus host diseases market. The World Health Organization (WHO) reports that the prevalence of GvHD is rising due to an increase in bone marrow and organ transplants. The increasing number of transplants is expected to drive market revenue growth. In addition, an increasing number of product approvals for the treatment of GvHD and rising illness detection rates are some of the factors driving the global graft versus host diseases market. According to the Leukemia & Lymphoma Society, chronic GvHD can occur in 30%-70% of allogeneic transplant recipients.
The growing number of clinical trials for GvHD is expected to drive market growth. For instance, a study conducted by the National Institute of Health in the United States discovered that a combination of ruxolitinib and sirolimus was effective in treating GvHD. The researchers concluded that combination therapy was safe and effective in treating GvHD.
Graft Versus Host Diseases Market Ecosystem
The global graft versus host diseases market has been analyzed from three perspectives: treatment type, disease type, and region.
Graft Versus Host Diseases Market by Treatment Type
[4654646]
Based on treatment type, the global graft versus host diseases market has been segmented into immunosuppressants, corticosteroids, mTOR inhibitors, tyrosine kinase inhibitors, monoclonal antibodies, and others.
The immunosuppressants segment dominates the global market. This trend is expected to continue during the forecast period due to an increase in the number of targeted drug therapies for treating acute and chronic GVHD with immunosuppressants. Moreover, the increase in populations suffering from conditions, such as cardiovascular disease, cancer, and nephrological disorders, also contributes to the growth of the graft versus host diseases market size. During the projection period, the corticosteroids is expected to be the fastest-growing segment as steroids are normally produced in modest amounts in the body, thereby demanding external administration. They aid in regulating several activities, including the immune system, inflammation reduction, and blood pressure control.
Graft Versus Host Diseases Market by Disease Type
Based on disease type, the global graft versus host diseases market has been segmented into acute GVHD, chronic GvHD, and prophylaxis GvHD.
The acute GVHD segment accounts for a significant revenue share of the market, owing to an increase in the geriatric population, a rise in the prevalence of GvHD, and a growth in the number of allogeneic transplants. The chronic GvHD is predicted to be the fastest-growing segment during the forecast period.
Graft Versus Host Diseases Market by Region
Based on region, the global graft versus host diseases market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global graft versus host diseases market in 2022. The high prevalence of GvHD due to growing transplantation procedures in the region is expected to boost the expansion of the market. According to a study released in 2018 by the National Center of Biotechnology Information, 30% to 50% of hematopoietic stem cell transplant recipients have acute GVHD. This translates to 5,500 patients per year developing acute GvHD. Around 50% of individuals with acute graft versus host illness will eventually develop chronic GvHD.
GvHD is a major cause of morbidity and mortality in stem cell transplant patients, and its prevalence is rising in Asia Pacific. During the forecast period, the Asia Pacific graft versus host diseases market is expected to grow at a rapid pace. The market is expanding due to an increase in the number of stem cell transplants, growth in awareness of stem cell transplants, and a rise in government initiatives to support stem cell research. Furthermore, the rising prevalence of cancers, such as leukemia, lymphoma, and multiple myeloma, is expected to fuel the development of the Asia Pacific graft versus host diseases market. The Asia Pacific market for graft versus host diseases is highly competitive, with several major players, such as F. Hoffmann-La Roche Ltd., Celgene Corporation, Bristol-Myers Squibb, Novartis AG, and Pfizer Inc. Key players are focusing on strategic initiatives, such as collaborations, product launches, mergers and acquisitions, and partnerships, to gain a strong foothold in the Asia Pacific graft versus host diseases market.
Graft Versus Host Diseases Market Competitive Landscape
The prominent market players in the global graft versus host diseases market include:
The global graft versus host diseases market is highly competitive and is dominated by a few key players. These players are focusing on developing innovative solutions for the treatment of GvHD. In addition, companies are also focusing on collaborations and partnerships to strengthen their position in the market. For instance, in 2020, Gilead Sciences and Kite Pharma announced a collaboration to develop a novel therapy for GvHD. The collaboration was expected to reduce the cost of GvHD treatment. Moreover, players are also focusing on expanding their product portfolios to gain a competitive advantage in the market. For instance, in 2020, Kite Pharma announced the launch of Yescarta, a novel therapy for GvHD. The product launch was expected to strengthen Kite Pharma’s position in the market. In addition to the key players, there are also several small and medium-sized players in the market. These players are focusing on developing innovative solutions for the treatment of GvHD. For instance, in 2020, Immunovant Inc. announced the launch of IMVT-1401, a novel therapy for GvHD. The launch of the product is expected to create opportunities for the company.
Graft Versus Host Diseases Market Strategic Developments
Asia Pacific is the key revenue growth region in the global graft versus host diseases market.
The increasing rate of bone marrow or hematopoietic stem cell treatment and the rising number of pipeline drugs are propelling the global market revenue growth.
The graft versus host diseases market is expected to be valued at US$11.12 billion by 2030.
The global graft versus host diseases market is expected to register a revenue CAGR of 14% during the forecast period.
Incyte Corporation, Janssen Pharmaceuticals Inc., and Abbvie Inc. are among the top market players.
*Insights on financial performance is subject to availability of information in public domain